Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tekmira Licenses Marina Biotech’s RNAi Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tekmira Licenses Marina Biotech’s RNAi Technology

To develop therapeutics that silence disease-causing genes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tekmira Pharmaceuticals has obtained a worldwide, non-exclusive license to a novel RNAi payload technology, Unlocked Nucleobase Analog (UNA), from Marina Biotech. The UNA technology will be used for the development of RNAi therapeutics to treat disease by silencing specific disease causing genes. Marina will receive an upfront payment plus milestone and royalty payments on products developed by Tekmira that use UNA technology. Financial terms were not disclosed.
 
“Our license to Marina’s UNA technology expands and diversifies our foundation of technologies that enable us to develop RNAi therapeutics. With Tekmira’s leading LNP delivery technology, a strong balance sheet, and access to multiple RNAi payload technologies, we are well positioned to aggressively advance multiple products into human clinical trials,” said Dr. Mark J. Murray, Tekmira’s president and chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics